Last edition
News about "Insilico Medicine"
Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal
According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.
Insilico Medicine | 28/01/2026 | By News Bureau
Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.
Insilico Medicine | 21/01/2026 | By News Bureau | 124
Insilico Medicine and Eli Lilly Expand Collaboration to Accelerate AI-Driven Drug Discovery
The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.
Insilico Medicine | 11/11/2025 | By Dineshwori | 288
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy